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Abstract
Traditionally, immunology has considered a meaningful antibody response to be marked by large amounts of high-affinity
antibodies reactive with the specific inciting antigen; the detection of small amounts of low-affinity antibodies binding to
seemingly unrelated antigens has been considered to be beneath the threshold of immunological meaning. A systems-
biology approach to immunology, however, suggests that large-scale patterns in the antibody repertoire might also reflect
the functional state of the immune system. To investigate such global patterns of antibodies, we have used an antigen-
microarray device combined with informatic analysis. Here we asked whether antibody-repertoire patterns might reflect the
state of an implanted tumor. We studied the serum antibodies of inbred C57BL/6 mice before and after implantation of
syngeneic 3LL tumor cells of either metastatic or non-metastatic clones. We analyzed patterns of IgG and IgM
autoantibodies binding to over 300 self-antigens arrayed on slides using support vector machines and genetic algorithm
techniques. We now report that antibody patterns, but not single antibodies, were informative: 1) mice, even before tumor
implantation, manifest both individual and common patterns of low-titer natural autoantibodies; 2) the patterns of these
autoantibodies respond to the growth of the tumor cells, and can distinguish between metastatic and non-metastatic
tumor clones; and 3) curative tumor resection induces dynamic changes in these low-titer autoantibody patterns. The
informative patterns included autoantibodies binding to self-molecules not known to be tumor-associated antigens
(including insulin, DNA, myosin, fibrinogen) as well as to known tumor-associated antigens (including p53, cytokeratin,
carbonic anhydrases, tyrosinase). Thus, low-titer autoantibodies that are not the direct products of tumor-specific
immunization can still generate an immune biomarker of the body-tumor interaction. System-wide profiling of
autoantibody repertoires can be informative.
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Introduction
Immunologists traditionally have focused their studies on strong
immunereactivatestodefined antigensinducedbyimmunizationor
by disease. However, in contrast to the discrete immune specificity
borne by individual T-cell or antibody-mediated immune reactions,
recent attention has been directed to global patterns formed by
collectives of low-titer antibody reactivities as indicative of immune-
system state in both health and disease [1,2,3,4,5,6]. These systems-
immunologystudiesofpatternsofantibodiesaredirectedtoanalyzing
the general immune state of the body [7,8]; their aim is not focused
exclusively on high-titer, demonstrably specific one-to-one antigen-
antibody binding reactions. Systems immunology repertoire pattern
studies have included Western blot analyses of autoantibodies to
undefined self-antigens in tissue extracts [2,9] and antibodies
measuredinmicrotiterELISAplatestosometensofnamedantigens
[10,11]. We have extended the study of global antibody patterns by
exploiting microarray technology to devise antigen chips capable of
measuring the patterns of antibody reactivity, low-level as well as
high-level, to many hundreds of defined antigens simultaneously
[1,3,12]. bioinformatics analysis of natural autoantibody reactivities
makes it possible to characterize common patterns of reactivity, for
example,inmicepatterns predictive ofa future autoimmune disease
[1].Inhumans,wehavereportedthepresenceofcommonpatternsof
IgM and IgA autoantibodies in the cord bloods of healthy newborn
humans, apparently arising from self-reactive immune activation in
utero [3]. Antigen microarrays have also been used to detect
autoantibodies to antigens known to be associated with particular
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6053autoimmune diseases [4,6,13,14]. Recently, attention has been
directed to cancer biomarker discovery using proteomic and
immunomic techniques [15,16].
The present study was done to learn whether inbred mice raised
under standard specific pathogen-free (SPF) conditions manifest
individual and common patterns of autoantibody reactivity and
whether common autoantibody patterns are responsive to the state
of an implanted syngeneic tumor. We refer to these reactivities as
autoantibody reactivities because the antibodies were detected by
their binding to self-molecules spotted on a microarray chip.
Moreover, in keeping with convention, we named particular
autoantibody reactivities by the names of the self-antigens they
bound on the chip. Given their low affinities, one cannot
determine whether the IgG autoantibodies were induced in a
response to any of the tested self-antigens. Nevertheless, the
conserved reactivity patterns document the effect of the tumor on
the global autoantibody repertoire.
We studied the serum IgG and IgM repertoires in C57BL/6
mice before and after implantation in the footpads with tumor cells
of either of two clones of the syngeneic Lewis lung carcinoma
(3LL), metastatic and non-metastatic [17,18]. The tumor cells
were either left to grow locally or the tumors were resected.
Resection of the metastatic D122 clone spurs the development of
lethal lung metastases; resection of the non-metastatic A9F1 clone
cures the mice. This paper reports that both individual and
common autoantibody reactivity patterns exist in inbred mice and
that common autoantibody patterns create signatures that
dynamically reflect the state of an implanted tumor. Autoantibody
reactivity patterns can thus serve as immune biomarkers [7] and
provide a general insight into the natural autoantibody repertoire
– the immunological homunculus [19]. A systems biology
approach to immune system patterns can complement the
traditional quest for discrete specificity.
Results
Experimental protocol
Male mice of the C57BL/6 inbred strain, 8-weeks old, were
bled and 8 days later were inoculated with 2610
5 3LL tumor cells;
the mice received either clone D122 or clone A9F. The metastatic
D122 clone lacks cell-surface expression of the H-2K
b MHC class
I molecule; this clone metastasizes to the lungs and kills the mice
following resection of local tumors when they reach a size of about
8 mm in diameter. The less virulent A9F1 clone of the 3LL tumor
expresses the H-2K
b MHC molecule, and resection of the local
tumor usually cures the mice [17,18]. The tumors in some of the
mice receiving each clone were resected when the tumors had
reached a size of about 8 mm in diameter; the remaining mice
were left with their locally growing tumors. Resection was followed
by lethal lung metastases in those mice bearing D122 tumors; the
resection cured the mice bearing A9F1 tumors. The mice with
unresected tumors were bled at day 33 post inoculation when the
local tumors had reached a diameter of about 18 mm. The mice
recovering from the A9F1 clone after its resection were bled on
days 43 and 56 post inoculation. The mice suffering from
metastasis of the D122 clone were bled on day 43 post inoculation
(17 days after resection), before being sacrificed. Figure 1 presents
a schematic representation of the experimental protocol. The
intensities of IgG and IgM antibodies binding to each of 327
antigens were measured individually and compared to the
reactivities detected in the healthy mice before they had received
the tumor-cell inoculation. We asked two general questions: do
inbred mice manifest individual and common autoantibody
reactivities to particular self-molecules and can common autoan-
tibody reactivities reflect the tumor state?
Healthy and tumor-bearing mice express individual and
common IgM and IgG autoantibody repertoires
Antibody reactivities that are common to individuals within a
group are marked by relatively little individual variation in
intensity. In contrast, antibody reactivities that markedly differ
between members of the group are characterized by relatively high
individual variation. The mean group antibody reactivities and the
standard deviations manifested by the serum IgM and IgG
repertoires binding to each antigen served to define common (low
variation) and individual (high variation) reactivities. We removed
from consideration 129 (IgM) and 124 (IgG) antigens to which
Figure 1. Time line of experimental procedures. Samples were collected several times during the development of each tumor (marked red),
and before and after resection (marked green). Black lines indicate the existence of a primary tumor; the orange line signifies a metastatic state (the
D122 clone) following resection and the blue line signifies resected mice with no metastases (the A9F1 clone). The numbers of mice in each group at
each time point can be seen in Table 1.
doi:10.1371/journal.pone.0006053.g001
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dilution (see supplementary Table S1) because uniformly low or
absent reactivities would manifest very little individual variation a
priori. We found that the mice expressed both individual and
common autoantibody reactivities both before and after they were
implanted with tumor cells (not shown). The reactivities
manifested by the mice before and after tumor implantation are
shown in Figure 2, depicted as 3D plots of the range of IgM and
IgG reactivities (Z axis) to sets of antigens (Y axis) in different mice
(X axis). The plots are colored to clarify differences. Panels a and b
illustrate the IgM and IgG reactivities in the healthy and tumor-
bearing mice to each antigen in a set of about 100 antigens with
relatively low variation within the group of healthy mice; Panels c
and d illustrate, by comparison, the IgM and IgG reactivities
manifested to a set of about 100 antigens with relatively high
variation. One can clearly see the uniformity among antigen
reactivities in panels a and b compared to the large range of
reactivities in Panels c and d. The antigens in each of these sets of
antibody reactivity are listed in Table 1. We found that the degree
of variation was not determined by the degree of reactivity, and
was similar before and after tumor inoculation. In other words,
antigens with a low or high variability before inoculation also had
a low or high variability, respectively, after inoculation (see
Figure 1, Supplementary Material). Thus we can conclude that
inbred C57BL/6 mice manifest common autoantibody reactivities
to some self-antigens and individual autoantibody reactivities to
other self-antigens. Are particular autoantibody reactivity patterns
associated with the growth of tumor cells?
No single autoantibody marks the tumor state
To detect the effects of tumor growth on the autoantibody
repertoire, we compared the serum taken from the mice before
and after the implantation of the tumor cells. Following the
inoculation of the tumor cells, some of the common autoanti-
body reactivities showed significant increases or decreases in the
group as a whole; most of the common autoantibody
reactivities, however, did not appear to respond to tumor
inoculation (data not shown). Actually, no single autoantibody
reactivity could discriminate between the pre-tumor and early
post-tumor states. In other words, the microarray analysis did
not detect a single tumor-associated reactivity. Moreover, the
degree of change in autoantibody repertoire in response to a
growing tumor was equally associated with both high and low
degrees of initial autoantibody reactivities. The absence of clear
tumor-associated antibodies to a single antigen may have
resulted from two factors: the antigens we spotted did not
include the hypothetical tumor-specific antigen, and/or our
quest was directed to a level of separation that was apparently
above the capacity of any single reactivity. Nevertheless, the
collective patterns of autoantibodies binding to the arrayed self-
antigens were informative.
Separation of healthy and tumor-bearing mice using all
the tested autoantibody reactivities
To test statistically the ability of the full repertoire to separate
tumor-bearing from healthy mice, we used a linear SVM and
tested the separation using a Leave One Out (LOO) test [20]. In
this method, one of the samples is left out during the initial training
of the SVM. The left-out sample is then used as a test to see if the
collective of reactivities measured on the chip could successfully
identify whether the left-out sample was from a healthy mouse or
from a tumor-bearing mouse. Using this method, we obtained an
accurate identification of the test sample in 88% of the IgG
reactivities and in 85% of the IgM reactivities. There was no
significant difference in the success of detection between the
healthy and tumor-bearing samples (see supplementary Table S2).
This level of success is significantly greater than chance
(x2
1~22,pv0:0001). Thus the repertoire of autoantibodies, as
measured by the antigen chip, is highly sensitive to the tumor-
bearing state.
Sets of autoantibody reactivities can mark a tumor
To characterize defined sets of autoantibody reactivities that
might create a tumor signature, we first tested the minimal
number of the antigens in the array that might be able to fully
separate the repertoire shared by tumor-bearing mice from the
repertoire shared by the mice before their inoculation with tumor
cells. The separation between the pre- and post-inoculation sera
was performed using a linear combination of antigen reactivities.
Autoantibodies to a set of antigens was said to fully separate the
two groups if a linear score of their reactivities could be computed
to be consistently positive for the pre-inoculation and negative for
the post-inoculation groups. We began the analysis using
essentially all the antigens and systematically decreased the
number of antigens. We found that a full separation between the
healthy and tumor-bearing repertoires could be obtained with
collectives of about 10–15 antigens for each antibody isotype
separately, using a combination of a feature selection algorithm
and an SVM [21], as described in the Supplementary Methods S1
section. We never found a combination of less than 7 antigen
reactivities that could perfectly separate the repertoires of the pre-
and post-tumor states.
Informative antigen sets
To identify autoantibody reactivity patterns indicative of the
tumor state, we compared the autoantibody patterns of the 23
healthy mice with a limited number of antigens developing in these
mice at two time points (25–30 days and 52 days) after they had
been inoculated with the tumor cells. We sought such sets using
feature selection algorithms (see Supplementary Methods S1
section). In view of the differences observed between IgG and
IgM reactivities (Table 1), we analyzed each antibody isotype
repertoire separately. The sets of antigen reactivities differed, but
many of the same antigens appeared over and over again in the
different lists, and many of the separating antigen reactivities
appeared more than would be predicted at random
(x2
202~4021,pv1:e{100) (Figure 3). Note that an auto-antigen
appearing in the separating set is not necessarily a ‘‘tumor-
associated antigen’’. It simply is an antigen sensitive to the general
perturbation induced by the tumor in the antibody repertoire. For
each antigen reactivity, its frequency of appearance and
cumulative weight across the runs were calculated, and the
reactivities were sorted accordingly. Figure 4 depicts the antigen
reactivities most frequently appearing in the separating sets.
Frequent antigen reactivities were almost always associated with
either a healthy state (positive weight), or a tumor-bearing state
(negative weight).
To test statistically the predictive ability of each antigen-
reactivity set obtained by using the SVM and Genetic Algorithm
approaches, we used the LOO test [20] to see if the list of
biomarker antigens could successfully identify whether the left-out
sample was from a healthy mouse or from a tumor-bearing mouse.
We obtained an accurate identification of the test sample in 93%
of the IgG reactivities and in 88% of the IgM reactivities tested in
the SVM set. There was no significant difference in accuracy
between the healthy and tumor-bearing samples. This level of
success is significantly greater than by chance (x2
1~22,pv0:0001).
Autoantibodies and Tumor State
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growth
To learn whether different stages of tumor growth were
associated with changes in autoantibody patterns, we compared
the 22 serum samples obtained from the mice bearing 5 mm
tumors (19–22 days after tumor-cell inoculation) with the 22 serum
samples obtained from these mice when they bore 18 mm
diameter tumors (33days after tumor-cell inoculation). An SVM
algorithm separated the two stages, with LOO success rates of 70–
90%. Hence we can conclude that common autoantibody
repertoires are also sensitive to tumor growth.
Clustering analyses of autoantibody reactivity patterns
associated with tumor state
We used a clustering analysis of the serum samples to gain some
insight into particular autoantibodies that might reflect the state of
the tumor. This clustering analysis was based on antigen
reactivities ranked by a Wilcoxon rank-sum test [22] for their
relative ability to discriminate between the groups being compared
(see supplementary Table S3 (I–III) in the Supplementary Data).
The numbers of samples available for the clustering studies were
too small to obtain statistical validation, nevertheless, the results
call attention to interesting trends and antigens. In the following
clustering figures (Figures 5, 6, 7), IgG reactivities are shown in the
left panels and IgM in the right panels; the columns represent
individual mice; the rows represent the antigens, named on the
right side of each panel; and the relative degrees of reactivity are
indicated by the range of colors, from dark blue (very low) to dark
red (very high).
It appears, for example, that autoantibody profiles can
distinguish between mice bearing the A9F1 and D122 clones of
the syngeneic 3LL tumor. Figure 5 shows the results of clustering
the A9F1 and D122 local tumors at 18 mm. The IgG repertoire
did not separate the two clone types (left panel), but the IgM
repertoire reactivities (right panel) successfully separated them.
Resecting each tumor at 8 mm also generated different effects
on the autoantibody patterns. Figure 6 shows the results of
Figure 2. Antibody intensities of common and individual repertoires. Three-dimensional plots of the range of log-intensities of IgM and IgG
reactivities (Z axis) to sets of antigens (Y axis) in individual samples (X axis) are shown. The colors are only to clarify differences. Panels a and b
illustrate the IgM and IgG reactivities in the healthy and tumor-bearing mice to each antigen in a set of about 100 antigens with relatively low
variation within the group of healthy mice (labeled homuncular antigens); Panels c and d illustrate, by comparison, the IgM and IgG reactivities
manifested to a set of about 100 antigens with relatively high variation (labeled varying antigens). The figure illustrates three observations: A) the log-
intensity has a wide, almost flat distribution showing large differences between different antigens; B) highly varying antigens manifest high variation
over most samples and are not limited to a specific group of mice; C) variation of the log-intensity is not a function of the average intensity.
doi:10.1371/journal.pone.0006053.g002
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IgM antibodies IgG antibodies
Shared Mean Non shared Mean Shared Mean Non shared Mean
Ab reactivities reactivity Ab reactivities reactivity Ab reactivities reactivity Ab reactivities reactivity
phospholipase D 1.10 Galectin-1 1.18 vasopresin 0.92 oligo C 1.50
p53-wt 0.74 GpC 1.08 4IBB(L) 0.89 poly-Lysine 1.40
tyrosinase 0.68 CpG 1.05 acid collagen 0.75 p53-peptide 7 1.21
c-protein 0.66 gliadin 0.96 PTH 0.73 glycerald3phosdehyd 0.98
pertusis toxin 0.63 oligo c 0.92 H28 0.66 poly-Asp 0.75
human MOG 0.59 AMP 0.92 tyrosinase 0.64 GpC 0.71
p53-peptide 9 0.58 e.coli LPS 0.92 Galectin-3 0.63 CpG 0.68
insulin 0.58 ssDNA 0.88 thyrosinase 0.62 p53-peptide 16 0.67
Acetyl cholinesterase 0.54 poly-lysine 0.65 pertusis toxin 0.58 AMP 0.63
oxytocin 0.52 ubiquitin 0.59 c-protein 0.49 catalase 0.58
KLH 0.49 galectin-3 0.58 insulin 0.48 phosphlipase d 0.51
thyrosinase 0.49 p53-peptide 7 0.58 rhMOG 0.46 p53-peptide 11 0.49
MIG 0.45 glycerald 3 phos dehyd 0.57 elastase 0.45 myosin 0.46
b cristallin 0.44 MIF 0.56 oxytocin 0.37 LDL 0.43
MART1 0.42 rat mog 35-55 0.52 GST 0.32 CTLA-4 0.43
HSP47 0.40 dsDNA 0.51 p53- peptide 9 0.32 MIG 0.42
LDL 0.36 C1Q 0.50 HSP60 0.29 brain extract 0.41
MAGE1 0.36 acid phosphatase 0.48 defensin 2 0.27 TCR bchain/pN12 0.41
4IBB(L) 0.33 p53-peptide 16 0.44 MOG peptide 35-55 0.26 C1Q 0.40
fibrin 0.28 hemoglobin a 0.44 lipid A 0.24 HSP60 0.37
poly - Arg 0.27 fibrinogen 0.42 neuropeptide y 0.24 thyroglubulin 0.31
oligo T 0.17 b2 glycoprotein 0.41 c peptide 0.22 MAGE1 0.31
PSA 0.16 p53-peptide 23 0.38 glucagon 0.22 p53-peptide 23 0.31
GAD 0.15 catalase 0.37 poly - Arginine 0.22 gliadin 0.29
OVA 0.14 HSP40 0.36 b cristallin 0.18 fibrinogen 0.29
neuropeptide y 0.12 IL-21 0.33 HSP47 0.14 TCR bchain/pC2C 0.29
p53-3 0.10 p53-peptide 11 0.31 INAPC 0.14 p53-peptide11-186 0.28
poly-Asp 0.09 CTLA4 0.31 b-amyeloid 0.12 TCR bchain/C1 0.26
actin 0.08 Oligo ATTA 0.31 MOBP/p78-89 0.10 PSA 0.25
salmonela antigen 140 0.08 gelsolin 0.21 MUPP 0.09 salmonela-LPS 0.25
IL-8 0.07 p53-peptide 12-168 0.21 SOD 0.06 fibronectin 0.22
HSP60-peptide 17 0.06 myosin 0.18 MMP2 0.04 TNF-alpha 0.20
heparin 0.05 cytokeratin 18 0.18 kinesin 0.04 annexin 37 0.19
elastase 0.05 oligo A 0.18 caspase 8 0.03 Acetyl cholinesterase 0.15
insulin b 0.05 hGST 0.15 beta-MSH 0.02 KLH 0.15
GST 0.04 TNF-alpha 0.14 MIF 0.02 acid collagen 0.14
PLP 0.04 substance p 0.14 HSP40 20.04 protamine sulfate 0.13
HSP60-peptide 30 0.02 peroxidase 0.14 vimentin 20.04 GAD 0.13
CA-125 0.01 thyroglobulin 0.12 hrMOG 20.04 HSP60- peptide 12 0.13
caspase8 0.00 vasopresin 0.11 cytokeratin 18 20.05 myeloperoxidase 0.12
protamine sulfate 20.01 annexin 67 0.11 complement C5 20.05 substance p 0.12
vimentin 20.02 collagenase 0.10 pepstatin a 20.06 e.coli LPS 0.11
HSP60-peptide34 20.04 HSP60-peptide 7 0.09 oligo T 20.08 ssDNA 0.10
hEGF 20.05 melatonin 0.09 hGST 20.08 b2 glycoprotein 0.07
defensin 2 20.07 hemoglobin b 0.09 oligo A 20.09 IL-21 0.07
factor 2 20.08 PTH 0.09 ANP 20.10 HSP60-peptide 2 0.07
big gastrin 20.11 enolase 0.07 insulin b 20.11 CA-125 0.06
acid collagen 20.12 HSP60-peptide 2 0.06 LPS 20.13 enolase 0.06
ANP 20.12 pg LPS 0.04 insulin a 20.15 IL-8 0.06
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Shared Mean Non shared Mean Shared Mean Non shared Mean
Ab reactivities reactivity Ab reactivities reactivity Ab reactivities reactivity Ab reactivities reactivity
spectrin 20.13 HSP70-peptide 30 0.04 spectrin 20.16 lactoferrin 0.04
LHRH 20.14 oligo TAT 0.02 HSP60-peptide 13 20.16 p53-peptide 8 0.02
p53-peptide 12 20.17 TNF-R 20.01 carcitonin 20.17 hemoglobin b 0.02
p53-peptide 15 20.19 p53-8 20.02 MMP3 20.17 TNF-R 0.02
glucagon 20.19 TCR bchain/pN12 20.02 plasmin 20.17 p53-peptide 24 0.00
HSP60 20.20 annexin 37 20.02 annexin 67 20.18 diabetes associated peptide 0.00
hr MOG peptide 94-112 20.21 HSP60 20.02 HSP70-peptide 13 20.18 LHRH 20.01
HSP70-peptide13 20.21 b2 microglubulin 20.03 p53-peptide 22 20.19 60-peptide 29 20.02
H28 20.21 myc bp 20.03 alpha-cristallin 20.20 b2 microglubulin 20.04
lipid A 20.22 alpha-cristallin 20.03 p53-wt 20.21 laminin 20.04
gst-NAPc 20.22 p53 mutant 20.05 myc bp 20.21 MART1 20.06
HSP60-peptide 37 20.23 lactoferrin 20.06 actin 20.21 peroxidase 20.07
tubulin 20.24 phospho ea 20.10 h4 20.21 gelsolin 20.07
MMP3 20.24 Dly 20.10 p53-peptide 25 20.21 CA19-9 20.11
carcitonin 20.24 p53-peptide 6 20.11 IL-4 20.22 GroEL 20.13
plasmin 20.25 oligo ATA 20.11 p53-peptide 3 20.24 a2-macroglubulin 20.14
beta-MSH 20.25 gamma-MSH 20.12 melatonin 20.25 IL-15 20.14
HSP60-peptide 16 20.26 TAAT 20.12 Dly 20.25 H13 20.15
p53-peptide 14 20.26 hEGF 20.13 thrombin 20.25 p53 mutant 20.16
protease 20.27 cytokeratin 8 20.15 70-peptide 12 20.26 p53-peptide 14 20.21
diabetes associated peptide 20.27 p53-peptide 11-186 20.17 gamma-MSH 20.26 rat MBP 20.22
b-amyeloid 20.28 HSP70-peptide 8 20.21 70-peptide 32 20.27 HSP60-peptide 4 20.24
c peptide 20.28 HSP70-peptide 9 20.29 endothelin 1 20.27 HSP60-peptide 24 20.24
MMP2 20.29 PPD 20.30 heparin 20.28 HSP70-peptide 36 20.25
gst MUPP1 20.29 p53-peptide 24 20.31 HSP70-peptide 37 20.28 ribonuclease a 20.25
HSP60-peptide 20 20.30 brain extract 20.31 HSP60-peptide 20 20.28 Galectin-1 20.25
SOD 20.33 70-peptide 26 20.31 TCR bchain/C2 20.28 Oligo ATTA 20.27
endothelin 1 20.34 melanostatin 20.32 HSP70-peptide 12 20.28 EGF 20.27
HSP70-peptide 10 20.36 laminin 20.32 HSP60-peptide 6 20.28 HSP65 20.27
ribonuclease a 20.36 TCR bchain/pC2C 20.33 p53-peptide 15 20.28 hemoglobin a 20.27
HSP70-peptide 37 20.36 rat MBP 20.34 HSP70-peptide 22 20.28 cytokeratin 8 20.28
GroEL 20.40 a2-macroglubulin 20.34 PLP 20.30 HSP60-peptide 30 20.29
kinesin 20.40 p53-peptide 26 20.34 fibrin 20.30 HSP70-peptide 31 20.29
HSP70-peptide 32 20.41 myeloperoxidase 20.37 hr MOG 94-112 20.33 tubulin 20.29
HSP70-peptide 12 20.41 salmonella-LPS 20.37 HSP60-peptide 32 20.34 HSP90 20.31
TCR bchain/C1 20.42 HSP60-peptide 12 20.40 melanostatin 20.34 tropomyosin 20.32
HSP70-peptide 36 20.42 HSP60-peptide 5 20.44 HSP60-peptide 16 20.35 HDL 20.32
thrombin 20.44 p53-peptide 2 20.44 HSP60-peptide 37 20.36 p53-peptide 12-168 20.33
HSP70-peptide 22 20.47 HSP70-peptide 14 20.45 endothelin 2 20.36 HSP60-peptide 17 20.34
HSP60-peptide 6 20.47 proinsulin 20.46 HSP70-peptide 11 20.36 HSP70-peptide 18 20.34
HSP70-peptide 40 20.50 tropomyosin 20.47 MBP 20.36 collagenase 20.36
IL-15 20.50 vitronectin 20.48 oligo ATA 20.37 protease 20.36
p53-peptide 21 20.49 H3 20.37 HSP60-peptide 10 20.37
H13 20.51 oligo TAT 20.37 HSP71 20.40
factor x 20.54 TCR-alpha2 20.38 HSP70-peptide 40 20.41
HSP70-peptide 30 20.39
HSP60-peptide 7 20.40
Healthy C57BL/6 mice manifest common autoantibody reactivities to some self-antigens and individual autoantibody reactivities to other self-antigens. Each reactivity
was divided by the median reactivity of each sample and the log of the reactivities was taken. Thus, values lower than zero represent values lower than the median for
the appropriate sample. The antigens were then divided by the variance of the log-reactivity over the healthy samples.
doi:10.1371/journal.pone.0006053.t001
Table 1. Cont.
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IgM and IgG antibodies to particular antigens separated the two
groups of mice; this is not surprising: the mice that bore D122
tumor were evolving towards death by metastasis, while those
bearing the A9F1 clone were cured. The mice that were cured of
the A9F1 tumor by resection were then bled again two weeks later
(30 days after resection), and the sera from both time points after
resection were clustered. Figure 7 shows that the second post-
resection sera manifested an autoantibody pattern that differed
from that found in the sera collected two weeks earlier.
We also looked for clusters of antigens that manifested a
correlated profile in response to changes over time in response to
A9F1 tumor growth and the resection. Figure 8 shows two sets of
correlated antigen reactivities measured in log-scale intensities.
Note the differences between the sets of antigen reactivities
marked by blue or red lines: The antigen reactivities marked in red
did not appear to change in their IgG binding reactivity during the
pre-tumor and A9F1 tumor growth periods; however tumor
resection was associated with an increase in their antibody
reactivity. The antigen reactivities marked in blue, in contrast,
manifested an increase in their IgG reactivities during early tumor
growth followed by a marked decrease in reactivity with the
removal of the A9F1 tumor. The IgG reactivity to this blue group
of antigens increased again two weeks after the resection. Thus
various antigen reactivities form sets defined by correlated
behavior associated with tumor growth or resection.
Discussion
In this paper, we studied the IgG and IgM antibody repertoires
of inbred C57BL/6 mice and the changes in these repertoires
associated with the state of implanted syngeneic tumor cells. We
used an antigen chip microarray that projected the serum
antibodies onto a selected set of 327 antigens, mostly self-antigens.
This projection cannot tell us about the immunogenic stimuli that
induced the antibodies, nor can it define the affinity or the
specificity of any particular antibody molecule or collective of
antibody molecules. Indeed, a positive antigen-binding signal
probably reflects a collective mixture of polyclonal and cross-
reactive serum antibodies binding to a variety of structural
epitopes exposed by each spotted antigen. This multiplex study
was not designed to identify particular tumor-associated antigens
that might have specifically immunized the tumor-bearing host.
Nevertheless, the projection of serum antibody reactivities on the
array of self-antigens provided a global view of reactivity patterns
within the autoantibody repertoire that were amenable to
detection and analysis by informatic techniques. Indeed, the
success of a large-scale pattern of autoreactivites to distinguish
between tumor-bearing and healthy mice suggests that patterns of
low-level autoantibodies might characterize the tumor state at least
as well as the long-sought, but frustratingly elusive tumor-specific
antibody.
Before implantation of the tumor cells, the healthy mice
manifested two types of autoantibody reactivity patterns detectable
at 1:5 serum dilution: a collective pattern common to the group
(marked by a relatively low degree of individual variation) and
individual patterns for each mouse (marked by a high degree of
variation between mice). The common pattern of C57BL/6 mice
was composed of some antigens to which there were strong and
consistent antibody reactivities and of other antigens to which
there were much weaker reactivities (Figure 2). The existence of
individual autoantibody reactivities is intriguing; the mice were
bred to possess identical genomes and lived in a seemingly
identical environment. Individual differences in autoantibody
reactivities, if not due to chance variation, suggest that the healthy
immune system can reflect quite subtle individual differences in
Figure 3. Specific antigens repeatedly separate test groups. Various informatic techniques generated multiple sets of antigen reactivities that
were able to successfully separate test groups of mice (pre-tumor and post-tumor mice, for example; see text and Table 2); some of these antigens
appeared with a high frequency in the various antigen sets. The frequency of appearance of these specifically successful antigens was significantly
greater than expected from a random distribution. Here is a representative plot of the antigen frequency for the lists of 25 antigens generated by a
Genetic Algorithm. The results were similar for the other methods. The thick full (IgM) and dashed lines (IgG) represents the antigen distribution in
the separating scores, while the thin dashed doted line is the expected distribution using a random choice at each stage.
doi:10.1371/journal.pone.0006053.g003
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infections and other strongly immunogenic stimuli. The immuno-
genic stimuli that generated the common autoantibody patterns
detected in the healthy mice are also unknown. Common
autoantibody patterns are not limited to inbred mice; the cord
bloods of healthy newborn humans manifest common IgM and
IgA autoantibody repertoires [23].
Interestingly, some of the common antigens bound by
autoantibodies in newborn human cord blood [19] were also
bound by the natural autoantibodies of the inbred C57BL/6 mice:
glutamic acid decarboxylase (GAD); myelin oligodendrocyte
glycoprotein (MOG); fibrin; HSP60 peptides; and HSP47. Other
human autoantibody reactivities appear in some but not all
C57BL/6 mice: galectins 1 and 3; beta2-microglobulin; gelsolin;
fibrinogen; annexin; and others (see Figure 4). Thus, some
autoantibody reactivities may be common to the two species,
some may be species-specific and some characterize individuals.
Note that both humans and mice manifest reactivities to linear
peptides of self-molecules, and these peptide reactivities may be
more prominent than the reactivities to the whole parent
molecule; see, for example, the IgG and IgM autoantibodies to
peptides of HSP60 and HSP70 in Figure 5. However, we need to
test many more samples on a wider range of arrayed self-molecules
before we draw firm conclusions about the scope of the
Figure 4. Significantly recurrent antigen reactivities mark tumor-bearing mice. Feature selection algorithms were used to detect sets of
antigen reactivities that marked mice subsequent to tumor inoculation and growth. The Table lists those reactivities that recurred with a significant
frequency among the different lists of informative antigens. The expected frequency of chance recurrence of each of these antigens in the various
lists is 0.05 and any frequency above 0.09 is significant (p,0.01). The bars represent frequencies of appearance of 0.1 or greater; the closed bars are
IgG reactivities and open bars are IgM reactivities. Note that six of the antigen reactivities were significantly frequent for both IgG and IgM reactivities:
fibrinogen, fibrin, protamine sulfate, SOD and two different peptides of p53.
doi:10.1371/journal.pone.0006053.g004
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these homuncular autoantibodies arise, why only some self-
antigens are recognized, why some reactivities are strong and
others weak, why some are shared and others individualized, and
what might be the evolutionary advantage of natural autoanti-
bodies prevalent in healthy individuals [23].
In the present study, we found that the implantation of
syngeneic tumor cells was associated with changes in autoantibody
reactivities. Note that no single autoantibody reactivity was found
to characterize the tumor state; it is conceivable that tumor-
specific autoantibody reactivities to a single tumor antigen do exist,
but such an antigen apparently was not included among those
arrayed on the chip. Nevertheless, the tumor state could still be
characterized by patterns composed of many autoantibody
reactivities binding to sets of self-antigens on the chip. In other
words, a specific biomarker may be generated by a pattern formed
by a collective of autoantibodies, and not necessarily by one
specific autoantibody [8]. Note that the tumors in this study arose
from the inoculation of pre-formed tumor cells; we are presently
investigating the effects on autoantibody patterns of a tumorigenic
process induced de novo by a chemical carcinogen.
At a more microscopic level of analysis, we used a clustering
method to detect autoantibody patterns associated with tumor
clonotype, tumor development, metastasis and curative resection
in the relatively small numbers of available mice. The results lead
to the general impression that the low-titer autoantibody
repertoire is indeed capable of dynamically registering changes
in tumor state [8]. Increasing the numbers of mice and the
numbers of molecules spotted on the microarray likely will shed
more light on the actual self-molecule indicators of the tumor state.
Nevertheless, the present results suggest some features worthy of
note: Informative low-titer autoantibody patterns include IgM
and/or IgG reactivities to molecules, a) known to associated with
tumors (p53, CA, PSA, MAGE, MART, cytokeratin), although
not necessarily known to be connected to the 3LL lung carcinoma;
b) known to be associated with autoimmune diseases, but not to
tumors (insulin, MOG, myosin, DNA); and c) not known to be
associated with either tumors or autoimmune diseases (gliadin,
fibrinogen, glucagon). Thus, low-level autoantibodies reflecting the
tumor state appear to include a cross-section of autoreactivities to
various antigens that can induce high titers of specific autoanti-
bodies associated with specific diseases.
The response of the autoantibody repertoire to the tumor state
generated several observations:
1. Individual mice inoculated with the same tumor cells manifest
common autoantibody reactivities; a tumor state can generate
an immune-system signature based on low-titer reactivities.
Figure 5. Clustering of antibody reactivities discriminates between mice bearing different tumor clones. Hierarchical clustering of IgG
(A) and IgM (B) antibody reactivities in mice bearing 18 mm
3 primary of the A9F1 and D122 clones based on separating antigens that were chosen
by the Wilcoxon rank-sum test in the array (see supplementary Table S3I, Supplementary Data). A color code denoting D122 (blue) and A9F1 (green)
samples is shown at the top and bottom. The color scale shows the relative degree of antibody binding from low (dark blue) to high (dark red). The
mice bearing different clones are separated by their IgM reactivities.
doi:10.1371/journal.pone.0006053.g005
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discrete; the immune system can undergo a generalized
response in which a pattern of reactivities can be more
informative than any single reactivity.
3. A tumor-state signature may include autoantibodies binding to
self-antigens not necessarily associated with the specific tumor.
4. Self-antigens associated with autoimmune diseases can serve as
components in a tumor signature in the absence of a clinically
overt autoimmune disease.
The findings support the idea that patterns of natural
autoantibodies – low-titer antibodies expressed in the absence of
designed immunization – can be informative of aspects of body
state [7]. It would be especially important to learn whether a
global analysis of autoantibody patterns might uncover immune
biomarkers useful in managing human tumors. Ultimately, the
low-level antibody repertoire may provide new ways for
diagnosing or predicting response to treatment of human tumors.
It thus appears possible to mine important information about the
state of the body using the thinking and the informatic tools of
systems immunology.
Methods
Cell cultures
The highly metastatic D122 clone and the non-metastatic A9F1
clone of the 3LL Lewis lung carcinoma, derived from the C57BL/
6 mouse, [17,18] were maintained in culture in DMEM
supplemented with 10% heat-inactivated fetal calf serum,
glutamine, combined antibiotics, sodium pyruvate and nonessen-
tial amino acids.
Mice
Eight-week old inbred C57BL/6 male mice were maintained in
the animal facilities of the Weizmann Institute of Science under
specific pathogen-free conditions. All animal experiments were
carried out with the approval of the Institutional Animal Care and
Use Committee of the Weizmann Institute, which meets the
standards, required by the UKCCCR guidelines and is recognized
by AAALAC International. Eight days after the first bleeding,
mice were divided into four groups. Groups 1 and 2, consisting of
10 mice each, were injected intra-footpad with 2610
5 D122 cells/
mouse. Groups 3 and 4, consisting of 10 mice each, were injected
Figure 6. Clustering of antibody reactivities discriminates between mice 17 days following resection of the different clones.
Hierarchical clustering of IgG (A) and IgM (B) reactivities for the A9F1 and D122 samples, collected 17 days post-resection, based on their reactivities
to separating antigens that were chosen by the Wilcoxon rank-sum test in the array (see supplementary Table S3II, Supplementary Data). A color code
denoting A9F1 (light blue) and D122 (pink) samples is shown at the top and bottom. The color scale shows the relative degree of antibody binding
from low (dark blue) to high (dark red). The groups are successfully separated both by IgM and IgG reactivities.
doi:10.1371/journal.pone.0006053.g006
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5 A9F1 cells/mouse. After 26 days, when the primary
tumors had reached 8 mm in diameter, the mice in groups 1 and 3
were anesthetized and the tumors were resected. We followed the
spread of metastases in mice in group 1 and the recovery and cure
of mice in group 3 (see Figure 1 for a time line of experimental
procedures and Table 2 for details of samples used in the analysis).
Mice with primary tumors were anesthetized and killed when
tumors reached .20 mm in diameter or when death from lung
metastasis appeared imminent.
Sera collection and bleeding schedule
Serum samples were collected before and at several time points
following tumor-cell inoculation (see Figure 1 for the timetable).
Blood was taken from the lateral tail vein, allowed to clot at room
temperature, and following centrifugation, the sera were stored at
220uC. Five ml of each sample were diluted (1:5) in PBS and then
incubated with the antigen-spotted slide for an hour at 37uC.
Previous studies have shown that informative patterns of low-titer
autoantibodies can be detected at dilutions of 1:5 or 1:10 (1, 3), but
this information is lost at higher titers of test serum [24]. The time
of bleeding and the stage of disease of each mouse are described in
Table 2. Mice that were bled at less than three measurement
points were removed from the data set.
Antigens and microarray preparation
Antigen microarrays were prepared as described previously [1].
We spotted 327 antigens, including proteins, synthetic peptides,
nucleotides, phospholipids, tumor associated and other self and
non-self molecules. See Supplementary Data, Table S4 for the full
list of antigens.
After incubation with the test sera, the arrays were developed
with a 1:500 dilution of detection antibodies. Two detection
antibodies were used in parallel on each microarray: a goat anti-
mouse IgG Cy3-conjugated antibody and a goat anti-mouse IgM
Cy5-conjugated antibody (purchased from Jackson ImmunoR-
esearch, West Grove, PA).
Data Analysis
The processed data set consists of two 327 by 73 matrices
of IgG and IgM reactivities. Each column contains the
reactivities measured on a given array (sample) and each row
contains the reactivities measured for a given antigen over all
arrays.
Raw data (after normalization, see below) were analyzed using
GeneSpringH software version 7 (Silicon Genetics, Redwood City,
CA) and Matlab (version 6.5.0.180913a, release 13; The Math-
Works).
Figure 7. Clustering of antibody reactivities discriminates between mice following resection of the A9F1 clone at different time
points. Hierarchical clustering of IgG (A) and IgM (B) reactivities 17 and 30 days after resection of the A9F1 tumors performed at 8 mm
3. The
separating antigens were chosen by the Wilcoxon rank-sum test (see supplementary Table S3III, Supplementary Data). A color code denoting early
(light blue) and late (blue) time points is shown. The color scale shows the relative degree of antibody binding from low (dark blue) to high (dark red).
The IgG and IgM reactivities both separated the groups.
doi:10.1371/journal.pone.0006053.g007
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PLoS ONE | www.plosone.org 11 June 2009 | Volume 4 | Issue 6 | e6053Figure 8. The dynamic response to correlated sets of antigens by mice bearing the A9F1 tumor. The figure shows the correlated
reactivities over time to two sets of antigens. The y axis represents the normalized intensity (log scale) level of the antibody reactivity to each antigen;
the x axis marks 4 time points in the history of the mice bearing the A9F1 tumor. The group of IgG reactivities to the antigens marked in red
manifested no change in intensity from the pre-tumor to the primary tumor state of 5 mm
3. Resection of the primary tumor was associated with an
increase in their antibody reactivity 17 days later with a fall in reactivity 30 days later. The reactivities to the antigens marked in blue, in contrast,
showed an increase in IgG reactivity (note the log scale) during primary tumor growth followed by a significant fall in reactivity early after resection
with a later rise. Thus, there appear to be correlated reactivities to sets of antigens.
doi:10.1371/journal.pone.0006053.g008
Table 2. Sample description.
Tumor type Group State Time of bleeding Pathology Number of microarrays
None 1,2,3,4 Pre-tumor prior to tumor cell inoculation None 23
D122 1,2 Early stage 22 days after cell inoculation 5–6 mm diameter 11
D122 2 Not resected 33days after cell inoculation 18 mm diameter 5
D122 1 Resected 26 days after inoculation 17 days after resection Metastasis onset 6
A9F1 3,4 Early stage 19 days after cell inoculation 5–6 mm diameter 12
A9F1 4 Not resected 33 days after cell inoculation 18 mm diameter 6
A9F1 3 Resected 26 days after inoculation 17 days after resection Recovery 4
A9F1 3 Resected 26 days after inoculation 30 days after resection Cured 6
Nine-week old mice were divided into four groups. Groups 1 and 2, consisting of 10 mice each, were injected intra-footpad with 2610
5 D122 cells per mouse. Groups 3
and 4, consisting of 10 mice each, were injected 2610
5 A9F1 cells per mouse. After 26 days, when the primary tumors had reached 8 mm in diameter, animals in groups
1 and 3 were anesthesized and the tumors were resected. We followed the spread of metastases in mice in group 1 and the recovery and cure of mice in group 3 (see
Figure 1).
doi:10.1371/journal.pone.0006053.t002
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Prior to normalization, any measurement value of less than 0.01
was set to an arbitrary cutoff value of 0.01. The data were then
normalized by dividing each slide array by its median intensity
value, thus producing comparable reactivity levels for different
slide arrays. The antigen reactivity was defined by the mean log
intensity measures of at least 4 replicate spots for that antigen on
each slide.
Filtering
The ‘Filtering by expression value’ option in GeneSpring was
used to eliminate antigens that do not meet a minimum cut-off
level in any of the tests; the cut-off signal intensity level was set to
590 for IgG and 100 for IgM reactivity. Thus, antigens that failed
to reach a reactivity level higher than the threshold in at least one
group were filtered out. Lists of reactive antigens are described in
supplementary Table S5 for IgG antibodies and in supplementary
Table S6 for IgM antibodies. Some of the antigens in these two
lists intersected; they were reactive in both IgG and IgM antibody
signal intensities.
Clustering analysis
Two different data sets were created, each one holding all
the sample reactivity for a particular isotype, IgG or IgM. We
used a Wilcoxon rank sum test to find significantly different
antigens separating each of the groups, and clustered the data
according to these antigens (denoted classifier antigens). The
Benjamini and Hochberg false discovery rate method [25] was
applied using a p-value of 0.05 to determine significance.
Hierarchical clustering was done using the distance measure
and the smooth correlation measure for the samples and
antigens, respectively (see GeneSpring for detailed description
of these measures). Supplementary Table S3 (I–III) describe
the p-values (using the Wilcoxson rank sum test) for the
classifier antigens for each of the different comparisons that are
presented in figures 4 through 6. Both the ‘cluster by
condition’ and cluster by genes’ (in our case antigens) functions
were used. Clustering by samples allowed samples with similar
behavior to be grouped together, while clustering by antigens
allowed us to test which antigens showed correlated behavior
over the samples.
Leave one out (LOO) test
We used a leave-one-out cross-validation. This method has been
shown to generate an essentially unbiased estimator of the
generalization properties of statistical models [20] and therefore
provides a reasonable criterion for model selection and compar-
ison. An advantage of this method is that the original data are used
to test a parameter set, which is yet being trained. It is therefore
very useful for small data sets. The current data set contains 23
pre-inoculation (healthy) samples and 34 post-inoculation (sick)
samples. To achieve the best solution, we used the LOO method
each time to test a sample (health or sick) that had been removed
from the training set.
Support Vector Machine (SVM)
For classification of autoantibody patterns we used a linear
SVM algorithm [21,26]. The SVM finds an optimal linear
hyerplane that separates two data sets, in our case tumor-bearing
and healthy mice, or mice bearing different tumor clones, and so
forth. The only parameter that needs to be specified in advance is
the slack variable coefficient.
Supporting Information
Figure S1 Standard deviation (StD) of log-reactivity in healthy
samples (first bleeding before inoculation) and sick samples (after
inoculation, but before resection). The standard deviations before
and after inoculations are highly correlated, showing that the same
antigens have a consistent low or high standard deviation (IgM:
R=0.707, p=1.e-30,IgG R=0.8112,p=1.e-46).
Found at: doi:10.1371/journal.pone.0006053.s001 (0.36 MB TIF)
Table S1 Antibody reactivities that were removed from the
analysis due to low reactivity and low variation among samples.
The mean antibody reactivities and the standard deviations
manifested by the serum IgM and IgG binding to each antigen
were calculated for each group of samples. We removed from
consideration 129 (IgM) and 124 (IgG) antigens to which there was
little or no meaningful reactivity because uniformly low or absent
reactivities would manifest very little individual variation a priori.
The signal intensity threshold for IgM and IgG reactivity were set
to 100 and 590 respectively, based on the GeneSpring ‘error-
model’ function.
Found at: doi:10.1371/journal.pone.0006053.s002 (0.14 MB
DOC)
Table S2 LOO classification success, using either IgG (second
row) or IgM (third row). Two classifications were performed. The
first classification (second and third columns) was between the
second and third bleeding. In this classification, all mice bore
tumors, and the only difference was the tumor size. The results
presented are the percentage of correct results. The second
classification (fourth and fifth columns) was between the first
bleeding and the second and third bleeding - between healthy and
tumor bearing mice.
Found at: doi:10.1371/journal.pone.0006053.s003 (0.03 MB
DOC)
Table S3 The p-values for the classifier antigens for each of the
different comparisons presented in figures 4 through 6. Two
different data sets were created, each one holding all the sample
reactivity for a particular isotype, IgG or IgM. We used a
Wilcoxon rank sum test to find significantly different antigens
separating each of the groups, and clustered the data according to
these antigens (denoted classifier antigens). The Benjamini and
Hochberg false discovery rate method was applied using a p-value
of 0.05 to determine significance. Wilcoxon rank-sum test p-values
for the separating antigens are presented between (I) the primary
tumors, A9F1 and D122, (II) A9F1 and D122-resected samples.
(III) 17-day the the 30-day post-resection A9F1 samples.
Found at: doi:10.1371/journal.pone.0006053.s004 (0.04 MB
DOC)
Table S4 The complete list of antigens that were spotted on the
microarray is shown. The antigen molecules are presented in
groups according to loosely defined groups: heat shock proteins or
peptides (HSP); tissue antigens; immune system molecules;
structural molecules; hormones; cellular metabolism molecules;
plasma proteins; synthetic antigens; tumor-associated and trans-
plantation-related antigens; p53 peptides; and other antigens.
Found at: doi:10.1371/journal.pone.0006053.s005 (0.30 MB
DOC)
Table S5 Informative antigens for IgG reactivity. Antigens that
manifested an IgG Ab reactivity level above the signal intensity
threshold (590) at least in one group of samples are shown (see also
the legend to supplementary Table 1).
Found at: doi:10.1371/journal.pone.0006053.s006 (0.03 MB
DOC)
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manifested an IgM Ab reactivity level above the signal intensity
threshold (100) at least in one group of samples are shown (See also
the legend to supplementary Table 1).
Found at: doi:10.1371/journal.pone.0006053.s007 (0.03 MB
DOC)
Methods S1
Found at: doi:10.1371/journal.pone.0006053.s008 (0.03 MB
DOC)
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